CN100344282C - Method for preparing rifamicina injecta - Google Patents
Method for preparing rifamicina injecta Download PDFInfo
- Publication number
- CN100344282C CN100344282C CNB2005100473608A CN200510047360A CN100344282C CN 100344282 C CN100344282 C CN 100344282C CN B2005100473608 A CNB2005100473608 A CN B2005100473608A CN 200510047360 A CN200510047360 A CN 200510047360A CN 100344282 C CN100344282 C CN 100344282C
- Authority
- CN
- China
- Prior art keywords
- solution
- injection
- rifamycin
- value
- production method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 4
- 238000002347 injection Methods 0.000 claims abstract description 33
- 239000007924 injection Substances 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims abstract description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940062280 rifamycin sodium Drugs 0.000 claims abstract description 26
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003708 ampul Substances 0.000 claims abstract description 11
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 9
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 9
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- 239000011521 glass Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract 2
- 229940001584 sodium metabisulfite Drugs 0.000 abstract 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 229910001873 dinitrogen Inorganic materials 0.000 abstract 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 6
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 229960003292 rifamycin Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229930189077 Rifamycin Natural products 0.000 description 3
- RAFHKEAPVIWLJC-OQQFTUDCSA-N Rifamycin O Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC5(OCC(=O)O5)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C RAFHKEAPVIWLJC-OQQFTUDCSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- RAFHKEAPVIWLJC-TWYIRNIGSA-N z67lem9p1w Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C1=C3C(=O)C2=C[C@]11OCC(=O)O1 RAFHKEAPVIWLJC-TWYIRNIGSA-N 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 2
- 241001655322 Streptomycetales Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- SQTCRTQCPJICLD-KTQDUKAHSA-N rifamycin B Chemical compound OC1=C(C(O)=C2C)C3=C(OCC(O)=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SQTCRTQCPJICLD-KTQDUKAHSA-N 0.000 description 2
- SQTCRTQCPJICLD-OQQFTUDCSA-N rifomycin-B Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(OCC(=O)O)c4c3C2=O SQTCRTQCPJICLD-OQQFTUDCSA-N 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 241001468213 Amycolatopsis mediterranei Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000218480 Streptomyces aurantiacus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940109171 rifamycin sv Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention relates to a method for producing a rifamycin sodium injection, which comprises the following steps: A, 1 ml to 100 ml of water for injection is added to 0.01 to 500 mg of sodium metabisulfite as an antioxidant for dissolving the sodium metabisulfite for use; 0.01 to 5 ml of a propanediol solvent for injection is added to a solution prepared in step A, and is uniformly stirred for use; 10 to 1000 mg of rifamycin sodium (by C37H47NO12) is added to a solution prepared in step B. The present invention has the essential technical scheme that a pH value is regulated to 4.8 to 6.69; activated carbon for injection is then added to the solution, wherein the content of the activated carbon is 0.1% of that of the solution; the activated carbon is stirred for 10 minutes, and carbon is removed by filtering; the solution passes though microporous filtering films with the diameters of 0.2 micrometer; 1 to 20 ml of water for injection is supplemented to the solution; after the content range is measured between 90.0 to 110.0%, the solution is filled into brown glass ampules with the volume of 1 to 20 ml; nitrogen gas is inflated into the ampules, and the ampules are sealed; the ampules are sterilized for 30 minutes at a temperature of 100 DEG C by circulating steam, and are cooled, checked and packaged; the rifamycin sodium injection is formed. The rifamycin sodium injection of the present invention prepared by controlling a pH value from 4.8 to 6.69 has low impurity content. The product has high quality and good therapeutic effects.
Description
(1) technical field
The present invention relates to a kind of production method of rifamycin sodium injection, particularly relate to the span of control of the pH value of rifamycin sodium injection.
(2) background technology
Rifamycin sodium injection is semi-synthetic rifomycins antimicrobial drug, specificity suppresses the activity of RNA polymerase in the tuberculosis thalline, suppresses the synthetic of bacteria RNA and tropina, causes bacterial reproduction to stop and reaching the sterilization purpose, with other antitubercular agent combined chemotherapy, Synergistic.This product can be used for treating each the paratuberculosis disease that is caused by mycobacterium tuberculosis, be used for the treatment of by the microbial following infection of sensitivity: respiratory tract infection, surgical infection, urinary tract infection, ophthalmology infect, and infect in otorhinolaryngology infection, peritonitis, cholecystitis, cholangitis and other abdomen; Septicemia, skin and soft tissue infection; Pelvic inflammatory disease, endometritis, gonorrhea and genital infection etc.Belong to the pharmaceuticals industry technical field.
Rifamycinoid antibiotics is nineteen fifty-seven to extract the antibiotic complex that obtains from the ferment filtrate of streptomycete (Streptomyces mediterranei), has obtained rifamycin-S (Rifamycin S) later on again from multiple other Pseudomonas.Rifamycin micromonospora (Micromonosporarifamycetica) S-190 that China finds and orange streptomycete (S.aurantiacus) 70-2032 can both directly produce rifamycin-S, and the strain of direct generation Rifamycin Sodium (Rifamycin SV) is also arranged.Rifamycinoid antibiotics has strong bactericidal action to gram positive bacteria and mycobacterium tuberculosis.Because of producing the difference of bacterium strain, various compositions such as obtaining rifamycin A, B, C, D, E, O, S and SV from ferment filtrate, have been separated, wherein a rifamycin B, O, S and SV are important, and conversion mutually, rifamycin B generates rifamycin-O through oxidation, rifamycin-O generates rifamycin-S through hydrolysis, and rifamycin-S generates Rifamycin Sodium through reduction.Rifamicina is a Chibro-rifamycin.
Rifamycin sodium injection belongs to Tri-Biocin.This product is the broad spectrum antibiotic of semi-synthetic rifamycin apoplexy due to endogenous wind.To staphylococcus aureus (comprising penicillin resistant and anti-neomycin strain), tubercule bacillus has stronger antibacterial action.A little less than common gram-negative bacteria effect.Its mechanism of action is the activity that suppresses ribonucleic acid polymerase in the thalline, thereby influence the synthetic and protein metabolism of ribonucleic acid, causes bacterial growth to be bred stopping and reaching bactericidal action.
So rifamicina malabsorption is clinical employing intramuscular injection or intravenous injection.Injection back distributes with liver and bile for the highest, also can reach treatment concentration at kidney, lung, the heart, spleen.Do not find crossing drug resistant as yet with other class antibiotic or antitubercular agent.
The present rifamycin sodium injection of producing, impurity content is higher, influences the curative effect of medicine.
(3) summary of the invention
Purpose of the present invention provides a kind of impurity content that reduces, the production method of the rifamycin sodium injection that improves the quality of products.
The technical scheme that adopts is:
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 0.01～500mg, add 1ml～100ml water for injection dissolving, standby;
B, get solvent for injection propylene glycol 0.01～5ml, join in the solution of A step preparation, stir and rise all, standby;
C, get rifamicina (with C
37H
47NO
12Meter), l0～1000mg joins in the solution of B step preparation, and its technical essential is that adjust pH is 4.8～6.69.Then, add needle-use activated carbon, stirred 10 minutes, filter carbon removal by 0.1% of solution amount, cross 0.2 μ m microporous filter membrane, water to 1～20ml is penetrated in after-teeming, measure content in the 90.0-110.0% scope after, fill is in l～20ml brown glass ampoule, and inflated with nitrogen seals; 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Characteristic of the present invention is to have determined that by a large amount of tests the span of control of pH value is 4.8～6.69.All the other technical processs are the already known processes process.The rifamycin sodium injection impurity content that is controlled at 4.8～6.69 preparations when pH value is low, product quality height, good effect.
(4) specific embodiment
Embodiment one
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 4mg, add the dissolving of 10ml water for injection, standby;
B, get solvent for injection propylene glycol 1ml, join in the solution of A step preparation, stir;
C, get rifamicina 50mg, join in the solution of B step preparation, regulate pH value to 4.85 with sodium hydroxide.Add needle-use activated carbon by 0.1% of solution amount then, stirred 10 minutes, filter carbon removal, after 0.2 μ m microporous filter membrane, after-teeming is penetrated water to 10ml, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals, 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Embodiment two
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 4mg, add the dissolving of 10ml water for injection, standby;
B, get solvent for injection propylene glycol lml, join in the solution of A step preparation, stir;
C, get rifamicina 50mg, join in the solution of B step preparation, regulate pH value to 5.5 with sodium hydroxide.Add needle-use activated carbon by 0.1% of solution amount then, stirred l0 minute, filter carbon removal, after 0.2 μ m microporous filter membrane, after-teeming is penetrated water to 10ml, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals, 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Embodiment three
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 4mg, add the dissolving of 10ml water for injection, standby;
B, get solvent for injection propylene glycol 1ml, join in the solution of A step preparation, stir;
C, get rifamicina 50mg, join in the solution of B step preparation, regulate pH value to 6.5 with sodium hydroxide.Add needle-use activated carbon by 0.1% of solution amount then, stirred 10 minutes, filter carbon removal, after 0.2 μ m microporous filter membrane, after-teeming is penetrated water to 10ml, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals, 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Embodiment four
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 4mg, add the dissolving of 10ml water for injection, standby;
B, get solvent for injection propylene glycol 1ml, join in the solution of A step preparation, stir;
C, get rifamicina 50mg, join in the solution of B step preparation, regulate pH value to 6.6 with sodium hydroxide.Add needle-use activated carbon by 0.1% of solution amount then, stirred 10 minutes, filter carbon removal, after 0.2 μ m microporous filter membrane, after-teeming is penetrated water to 10ml, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals, 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Embodiment five
A kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 4mg, add the dissolving of 10ml water for injection, standby;
B, get solvent for injection propylene glycol 1ml, join in the solution of A step preparation, stir;
C, get rifamicina 50mg, join in the solution of B step preparation, regulate pH value to 6.65 with sodium hydroxide.Add needle-use activated carbon by 0.1% of solution amount then, stirred 10 minutes, filter carbon removal, after 0.2 μ m microporous filter membrane, after-teeming is penetrated water to 10ml, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals, 100 ℃ of sterilizations of circulation steam 30 minutes, cooling, check, packing, promptly.
Claims (6)
1, a kind of production method of rifamycin sodium injection comprises the steps:
A, get antioxidant sodium pyrosulfite 0.01～4mg, add 1ml～10ml water for injection dissolving, standby;
B, get solvent for injection propylene glycol 0.01～5ml, join in the solution of A step preparation, stir and rise all, standby;
C, get rifamicina, with C
37H
47NO
12Meter 10～1000mg joins in the solution of B step preparation, regulates pH, then, add needle-use activated carbon by 0.1% of solution amount, stirred 10 minutes, filter carbon removal, cross 0.2 μ m microporous filter membrane, water to 1～20ml is penetrated in after-teeming, measure content in the 90.0-110.0% scope after, fill is in 1～20ml brown glass ampoule, inflated with nitrogen seals; 100 ℃ of sterilizations of flowing steam 30 minutes, cooling, check, packing promptly, is characterized in that adjust pH is 4.8～6.69.
2, the production method of a kind of rifamycin sodium injection according to claim 1, it is characterized in that transferring the solution pH value is 4.85.
3, the production method of a kind of rifamycin sodium injection according to claim 1, it is characterized in that transferring the solution pH value is 5.5.
4, the production method of a kind of rifamycin sodium injection according to claim 1, it is characterized in that transferring the solution pH value is 6.5.
5, the production method of a kind of rifamycin sodium injection according to claim 1, it is characterized in that transferring the solution pH value is 6.6.
6, the production method of a kind of rifamycin sodium injection according to claim 1, it is characterized in that transferring the solution pH value is 6.65.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100473608A CN100344282C (en) | 2005-10-09 | 2005-10-09 | Method for preparing rifamicina injecta |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100473608A CN100344282C (en) | 2005-10-09 | 2005-10-09 | Method for preparing rifamicina injecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1742718A CN1742718A (en) | 2006-03-08 |
| CN100344282C true CN100344282C (en) | 2007-10-24 |
Family
ID=36138346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100473608A Active CN100344282C (en) | 2005-10-09 | 2005-10-09 | Method for preparing rifamicina injecta |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100344282C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101153274B (en) * | 2006-09-29 | 2010-12-01 | 中国科学院上海生命科学研究院 | Method for improving volume of production of rifamycin |
| CN101152174B (en) * | 2007-09-11 | 2011-12-14 | 沈阳药科大学 | Stable rifamycin sodium injection prescription and preparing method of the same |
| CN102579327A (en) * | 2012-02-12 | 2012-07-18 | 王伟志 | Rifamycin SV sodium injection and preparation method thereof |
| CN104107163B (en) * | 2014-02-28 | 2016-05-18 | 江西赣南海欣药业股份有限公司 | A kind of rifamicina VC Pharmaceutical composition injection preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101258A (en) * | 1993-10-04 | 1995-04-12 | 曾永保 | Production of composite medicine liq. containing rifamycin antibiotic |
-
2005
- 2005-10-09 CN CNB2005100473608A patent/CN100344282C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101258A (en) * | 1993-10-04 | 1995-04-12 | 曾永保 | Production of composite medicine liq. containing rifamycin antibiotic |
Non-Patent Citations (1)
| Title |
|---|
| 化学工业出版社 国家药典委员会，国家药品标准化学药品标准上升国家标准，第2卷 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1742718A (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102871996B (en) | Antibiotic composition and application thereof | |
| Tan et al. | Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia | |
| CN101080230A (en) | Treatment and control of severe infections including cystic fibrosis | |
| Schentag et al. | Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia | |
| CN100344282C (en) | Method for preparing rifamicina injecta | |
| EP3903827A1 (en) | Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof | |
| JP2961182B2 (en) | Pharmaceutical composition for prevention and treatment of Clostridium difficile diarrhea and pseudomembranous colitis | |
| US20210283215A1 (en) | Bacteriotherapy against proprionibacterium acnes for the treatment of acne | |
| WO2011132943A9 (en) | Composition for treatment of acute pseudomembranous colitis | |
| CN112999220B (en) | Application of alpha-lipoic acid as and/or preparing metallo-beta-lactamase inhibitor | |
| CN108403676B (en) | Application of succinic acid in improving sensitivity of bacteria to antibiotics | |
| CN110946870A (en) | Antibacterial pharmaceutical composition and application thereof | |
| CN102949397B (en) | Cefotaxime sodium and tazobactam sodium preparation for injection and preparing method thereof | |
| US20060073156A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
| CN112438975B (en) | Application of diabetes treatment medicine in bacteriostasis | |
| CN110402139A (en) | The method for treating bacterium infection | |
| CN110711192A (en) | Use of tryptophan for enhancing gram-negative bacteria bactericidal effect | |
| CN115369061A (en) | Selective helicobacter pylori culture medium and preparation method thereof | |
| CN108066338A (en) | New antibiotic composition when prevention and treatment aerobic bacteria and anaerobic bacteria mixed infection and preparation method thereof | |
| CN101849947A (en) | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium | |
| CN113637025B (en) | Cefotaxime magnesium compound, preparation method and application thereof | |
| CN1203862C (en) | Compound glucose injection with clindamycin and metronidazole | |
| CN111249292B (en) | Antibacterial pharmaceutical composition and preparation method and application thereof | |
| CN102266326B (en) | Imipenem and cilastatin sodium pharmaceutical composition liposome injection | |
| LeFrock et al. | Cefoxitin therapy in aerobic, anaerobic, and mixed aerobic-anaerobic infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG SHUANGDING TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHUANGDING PHARMACEUTICAL CO., LTD., SHENYANG Effective date: 20081024 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081024 Address after: Hi Tech road Shenyang city Liaoning Province Hunnan New District No. 15 Patentee after: Shenzhen Shuangding Technology Co.,Ltd. Address before: Hi Tech road Shenyang city Liaoning Province Hunnan New District No. 15 Patentee before: Shenyang Shuangding Pharmaceutical Co.,Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Ma Zhanzhi Inventor after: Wang Dongkai Inventor after: Li Zhiqiang Inventor after: Wang Zunlai Inventor before: Ma Zhanzhi Inventor before: Wang Dongkai Inventor before: Li Zhiqiang Inventor before: Wang Zunlai |
|
| CP03 | Change of name, title or address |
Address after: Shenyang City, Liaoning province high tech road 110179 No. 15 Room 201 Hunnan Patentee after: Shenyang stone West Investment Co.,Ltd. Address before: Hi Tech road Shenyang city Liaoning province 110179 Hunnan New District No. 15 Patentee before: Shenzhen Shuangding Technology Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170607 Address after: Hi Tech road Shenyang city Liaoning province 110179 Hunnan New District No. 15 Patentee after: Shenyang Shuangding Pharmaceutical Co.,Ltd. Address before: Shenyang City, Liaoning province high tech road 110179 No. 15 Room 201 Hunnan Patentee before: Shenyang stone West Investment Co.,Ltd. |
|
| TR01 | Transfer of patent right |